First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

May 5th 2025, 3:00pm

By Ryan Scott

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.

Navigating Treatment After Progression: Testing, ESR1 Mutations and Tolerable Options

May 5th 2025, 3:00pm

By Virginia Kaklamani, MD, DSc

Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering patient-specific factors.

Cancer Survivor Raises AYA Awareness After Rare Lymphoma Diagnosis

May 5th 2025, 1:00pm

By Spencer Feldman

In this Q&A, Carly Stafford Dixon discusses her lymphoma journey, recovery with CAR T therapy, and mission to raise support for young adults with cancer.

POIESIS Trial Explores Navtemadlin Plus Jakafi for Myelofibrosis

May 5th 2025, 12:00pm

By Ryan Scott

The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.

An Expert Offers Advice and Resources for Navigating Rare Lymphoma

May 4th 2025, 6:00pm

By Ryan Scott

Dr. Neha Mehta-Shah shares how patients can better understand their subtype of rare lymphoma, as well as expands on the challenges these patients face.

Celebrating an Expert at Emotional Support

May 4th 2025, 2:00pm

By ELIZABETH ASHWORTH B.S.N., RN, OCN

It is with great pride and admiration that I nominate Diane Hudson, RN, OCN, for the Extraordinary Healer Award for Oncology Nursing.

Dr. Eng Breaks Down Braftovi Plus Erbitux FDA Approval in BRAF+ mCRC

May 3rd 2025, 6:00pm

By Dr. Cathy Eng

Dr. Cathy Eng discusses the importance of the Braftovi plus Erbitux FDA approval for treatment-naive BRAF V600E+ metastatic colorectal cancer.

A Healer’s Touch During My Experience With Cancer Care

May 3rd 2025, 2:00pm

By Jeff Gaard

The Calm of Unbroken Kindness

May 2nd 2025, 9:00pm

By Julie Smith, MBA/MHSM, B.S.N., RN, OCN

The nursing profession is home to countless extraordinary.

Breaking Down the Benefits of Clinical Trial Participation in Cancer Care

May 2nd 2025, 8:00pm

By Dr. Scott T. Tagawa

Dr. Scott T. Tagawa discusses what patients with prostate cancer should know about the potential benefits and risks of participating in a clinical trial.

Smoking Data May Guide Improved Lung Cancer Care and Patient Support

May 2nd 2025, 7:00pm

By Dr. Daniel J. Boffa

Most patients in accredited hospitals had smoking discussions documented, showing key care opportunities and smoking’s impact on treatment outcomes.

Renewal and Healing from Testicular Cancer This May

May 2nd 2025, 5:00pm

By Brian Sluga

After testicular cancer, I’ve learned to guard my mood, seek small joys and embrace healing and renewal with every sunrise this spring.

First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer

May 2nd 2025, 4:00pm

By Ryan Scott

The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 DENALI clinical trial.

Pretreatment Baseline Screening for Breast Cancer-Related Lymphedema

May 2nd 2025, 3:00pm

By Spencer Feldman

New results from a breast cancer-related lymphedema study show the importance of measuring fluid and body composition before treatment begins.

Dosing of PAS-004 Begins in Patients in MAPK-Driven Tumors

May 2nd 2025, 1:00pm

By Spencer Feldman

Enrollment and initial dosing of PAS-004 at 30 milligrams has begun in three patients with MAPK pathway-driven advanced solid tumors.